Literature DB >> 10029064

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.

M Esteller1, S R Hamilton, P C Burger, S B Baylin, J G Herman.   

Abstract

The DNA repair protein O6-methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the O6 position of guanine. MGMT expression is decreased in some tumor tissues, and lack of activity has been observed in some cell lines. Loss of expression is rarely due to deletion, mutation, or rearrangement of the MGMT gene, but methylation of discrete regions of the CpG island of MGMT has been associated with the silencing of the gene in cell lines. We used methylation-specific PCR to study the promoter methylation of the MGMT gene. All normal tissues and expressing cancer cell lines were unmethylated, whereas nonexpressing cancer cell lines were methylated. Among the more than 500 primary human tumors examined, MGMT hypermethylation was present in a subset of specific types of cancer. In gliomas and colorectal carcinomas, aberrant methylation was detected in 40% of the tumors, whereas in non-small cell lung carcinomas, lymphomas, and head and neck carcinomas, this alteration was found in 25% of the tumors. MGMT methylation was found rarely or not at all in other tumor types. We also analyzed MGMT expression by immunohistochemistry in relation to the methylation status in 31 primary tumors. The presence of aberrant hypermethylation was associated with loss of MGMT protein, in contrast to retention of protein in the majority of tumors without aberrant hypermethylation. Our results suggest that epigenetic inactivation of MGMT plays an important role in primary human neoplasia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029064

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  397 in total

Review 1.  Serrated adenoma of the colorectum: a lesion with teeth.

Authors:  Jeremy R Jass
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

Review 2.  Treatment considerations for MGMT-unmethylated glioblastoma.

Authors:  Jennie W Taylor; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

Review 3.  Epigenetic changes of DNA repair genes in cancer.

Authors:  Christoph Lahtz; Gerd P Pfeifer
Journal:  J Mol Cell Biol       Date:  2011-02       Impact factor: 6.216

4.  Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma.

Authors:  Wen-Hua Xiao; Wei-Wen Liu
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

Review 5.  Flipping the epigenetic switch.

Authors:  Frederick E Domann; Bernard W Futscher
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

6.  Epigenetic Regulation of ZBTB18 Promotes Glioblastoma Progression.

Authors:  Vita Fedele; Fangping Dai; Anie P Masilamani; Dieter H Heiland; Eva Kling; Ana M Gätjens-Sanchez; Roberto Ferrarese; Leonardo Platania; Doostkam Soroush; Hyunsoo Kim; Sven Nelander; Astrid Weyerbrock; Marco Prinz; Andrea Califano; Antonio Iavarone; Markus Bredel; Maria S Carro
Journal:  Mol Cancer Res       Date:  2017-05-16       Impact factor: 5.852

7.  p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.

Authors:  Eduard B Dinca; Kan V Lu; Jann N Sarkaria; Russell O Pieper; Michael D Prados; Daphne A Haas-Kogan; Scott R Vandenberg; Mitchel S Berger; C David James
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

8.  Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.

Authors:  Rikke H Dahlrot; Pia Larsen; Henning B Boldt; Melissa S Kreutzfeldt; Steinbjørn Hansen; Jacob B Hjelmborg; Bjarne Winther Kristensen
Journal:  J Neuropathol Exp Neurol       Date:  2019-07-01       Impact factor: 3.685

Review 9.  Beyond genetics--the emerging role of epigenetic changes in hematopoietic malignancies.

Authors:  Oliver Galm; Manel Esteller
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

10.  Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

Authors:  Michael D Prados; Susan M Chang; Nicholas Butowski; Rebecca DeBoer; Rupa Parvataneni; Hannah Carliner; Paul Kabuubi; Jennifer Ayers-Ringler; Jane Rabbitt; Margaretta Page; Anne Fedoroff; Penny K Sneed; Mitchel S Berger; Michael W McDermott; Andrew T Parsa; Scott Vandenberg; C David James; Kathleen R Lamborn; David Stokoe; Daphne A Haas-Kogan
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.